Company Overview of Andromeda Biotech Ltd.
Andromeda Biotech Ltd. develops and manufactures drugs for the treatment of autoimmune diabetes. It offers DiaPep277, a product in Phase III clinical trial for treating Type 1 diabetes (T1D). The company’s clinical trial product, DiaPep277 is a peptide that represents a therapeutic approach to prevent the destruction of insulin producing cells in the pancreas. Its DiaPep277 product serves newly diagnosed adults, children, and adolescents with T1D; LADA patients; and people with a high risk of developing T1D. The company was founded in 2007 and is based in Yavne, Israel. As of June 12, 2014, Andromeda Biotech Ltd. operates as a subsidiary of Hyperion Therapeutics, Inc.
42 Hayarkon Street
Founded in 2007
972 8 938 7777
972 8 940 7737
Key Executives for Andromeda Biotech Ltd.
Andromeda Biotech Ltd. Key Developments
Similar Private Companies By Industry
|Abital Pharma Pipelines Ltd.||Middle East/Africa|
|Active PX Ltd.||Middle East/Africa|
|Advanced Inhalation Technology Ltd.||Middle East/Africa|
|Advanced Inhalation Therapies (AIT) Ltd.||Middle East/Africa|
|Angio B Ltd.||Middle East/Africa|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Andromeda Biotech Ltd., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.